> Method for modulating cell apoptosis (J Van Damme et al, BE)
Ludwig Institute for Cancer Research and the inventors N” WO 97110361, PCT. The invention is based upon the newly recognized ability of b chemokines to inhibit cell apoptosis. In particular, apoptosis of T cells is described. The known p chemokines I309 and T&%-3 are examples of the p chemokines which inhibit apoptosis. One aspect of the invention is the use of these molecules to inhibit apoptosis.
> Compounds and methods for immunotherapy and diagnosis of tuberculosis (SG Reed et a/, US)
Corixa Corporation N” WO 97/09429,
97/09428 PCT.
ET
Such compounds may be formulated into vaccines and/or pharmaceutical compositions or immunization against M tuberculosis infection, or may be used for the diagnosis of tuberculosis. ...
Kansas State University Research Foundation N” WO 97108944, PCT. A recombinantly derived insect chitinase gene is inserted into a vector for host expression of the chitinase protein, and may be utilized according to methods for controlling a population of pests (eg insects). A recombinant virus is provided for this purpose, as well as a recombinant plant. Recombinantly derived insect chitinase also may be expressed in host cells or larvae for subsequent purification.
> S6quence d’acides nucleiques et plasmides comprenant au moins un mbcanisme de r&istance aux phages, bact&ies les contenant et leur utilisation (F Prevots et al, FR)
Systems Bio-Industries N” 764723,
EP ET 764724,
EP.
L’invention a pour objet une skquence d’ ADN de 817 pb comprenant au moins un mCcanisme de rPsistance aux phages obtenus 1 partir de I’ADN total contenu dam la souche Lactococcus lactis ssp cremoris...
r Improved AAV vectors for gene therapy (SC Wadsworth et al, US)
> Processing of cellulosic materials by cellulase producing bacteria (HC Dees,
Genzyme Corporation the inventors
US)
N” WO 97109441,
and
PCT.
The present invention is directed to methods for generating high titer, contaminant free, recombinant AAV vectors, methods and genetic constructs for producing AAV recombinant vectors conveniently and in large quantities, methods for the delivery of all essential viral proteins required in trans for high yields of recombinant AAV, recombinant AAV vectors for use in gene therapy...
B Recombinant and use thereof tide (KJ Kramer W
chitinase as a bioet al, US,
Lockheed Martin Energy Systems N” WO 97/l 0352, PCT. Bacteria which produce large amounts of cellulase, as well as other enzymes, have been identified. The original bacterium (ATCC 55703) was genetically altered using nitrosoguanidine (MNNG) treatment to produce the enhanced cellulase producing bacterium (ATCC 55702), which was identified through replicate plating. > Methods of using nucleotide integrase for cleaving DNA and attaching nucleic acids (AM Lambowitz et al, US)
The Ohio State Research Foundation N” WO 97110362, PCT. One method uses a nucleotide integrase to cleave one strand of a double-stranded DNA and to concominantly
attach a nucleic acid molecule to the cleaved strand. Another method uses a nucleotide integrase to cleave both strands of a doublestranded DNA substrate and to attach a nucleic acid molecule to one strand of the DNA substrate...
> Fermentative production of vitamin 6, (K lchikawa et al, JP)
F Hoffmann-La Roche AG N” 765938, EP. A process for producing vitamin B, comprises cultivating a microorganism belonging to the genus Rhizohium and being capable of producing vitamin B, in a culture medium under aerobic conditions, and separating the resulting vitamin B, from the fermentation broth. z= A human metalloproteinase, variants thereof and DNA sequences coding therefor (AJ Docherty et PM Slocombe, UK)
Celltech Therapeutics Ltd and the inventors N” WO 97/09430, PCT. A human metalloproteinase is described together with nucleic acids coding therefor and corresponding antisense DNA and RNA. The metalloproteinase may be used to generate antibodies therefor and to obtain other compounds capable of regulating the action of the metalloproteinase in vivo. > Alkaliphilic and thermophilic microorganisms and enzymes obtained therefrom (BE Jones et a/, UK, W
Genencor International Inc and the inventors N” WO 97110342, PCT. The present invention provides thermophilic alkaliphilic bacteria and thermostable alkaline polypeptides obtainable therefrom. It also provides a method for producing polypeptides according to the invention, nucleic acids encoding such polypeptides and compositions comprising such polypeptides. It also relates to the use of enzymes obtainable from these novel organisms in the detergent industry, the paper and pulp
industry and the textile industry. > Process, apparatus and microorganism strain for the manufacture of citric acid (M Minarik et al, SK)
Likospol SRO and the inventors N” WO 97110350, PCT. The invention provides a process for producing highly purified citric acid. A citric acid broth is produced by fermentation from a carbohydrate substrate (sucrose, saccharose, glucose, dextrose, hydrolysed starch) using a selected strain of Aspergillus niger... The new A niger strain CC,M 8210 according to the invention has the ability to start the fermentation at a pH at least as low as 4, eg 2.8 and continue the fermentation until the pH of the substrate has droppedd at least as low as pH 1.4 at which stage the sugar level has dropped to not more than 1 000 mg/l and the ratio of citric acid to residual sugar may be as high as 275 : l-300 : l... > Production of lysosomal enzymes in plant-based expression systems (DN Radin et a/, US)
Virginia Tech Intellectual Property Inc and Croptech Development Corporation N” WO 97/l 0353, PCT. The invention relates to the production of enzymatically active recombinant human and animal lysosomal enzymes involving construction and expression of recombinant expression constructs comprising coding sequences of human or animal lysosomal enzymes in a plant expression system... The invention is demonstrated by working examples in which transgenic tobacco plants having recombinant expression constructs comprising human hGC and IDUA nucleotide sequences produces enzymatically active modified human glucocerebrosidase and human a-l-iduronidase. Les brevets peuvent etre obtenus A I’lnstitut national de la propri& industrielle (Inpi), 26, rue de SaintPBtersbourg, 75800 Paris cedex 08, 00 des copies peuvent itre fournies sur simple demande. selon les tarifs en vlgueur.
BIOFUTUR168 l Juin 1997 83